Activation of conventional PKCs (cPKC) is a key signaling that directs the cardiac toxicity of hyperglycemia. AKAP150, a scaffold protein of the A-kinase anchoring proteins (AKAPs) family, is less defined regarding its capability to anchor and regulate cardiac cPKC signaling. This study was designed to investigate the role of AKAP150 in cPKC-mediated cardiac glucotoxicity. In cardiac tissues from streptozotocin-induced diabetic rats and high-glucose-treated neonatal rat cardiomyocytes, both mRNA and protein levels of AKAP150 increased significantly, and marked elevations were observed in cPKC activity and both expression and phosphorylation levels of p65 NF-B and p47 phox . AKAP150 knockdown was established via intramyocardial injection in vivo and transfection in vitro of adenovirus carrying AKAP150-targeted shRNA. Downregulation of AKAP150 reversed diabetesinduced diastolic dysfunction as manifested by decreased left ventricular end-diastolic diameter and early/late mitral diastolic wave ratio. AKAP150 inhibition also abrogated high-glucose-induced cardiomyocyte apoptosis (TUNEL staining and annexin V/propidium iodide flow cytometry) and oxidative stress (ROS production, NADPH oxidase activity, and lipid peroxidation). More importantly, reduced AKAP150 expression significantly inhibited high-glucose-induced membrane translocation and activation of cPKC and suppressed the increases in the phosphorylation of p65 NF-B and p47 phox . Immunofluorescent coexpression and immunoprecipitation indicated enhanced anchoring of AKAP150 with cPKC within the plasma membrane under hyperglycemia, and AKAP150 preferentially colocalized and functionally bound with PKC␣ and -␤ isoforms. These results suggest that cardiac AKAP150 positively responds to hyperglycemia and enhances the efficiency of glucotoxicity signaling through a cPKC/p47 phox /ROS pathway that induces myocardial dysfunction, cardiomyocyte apoptosis, and oxidative stress.
AKAP150; conventional PKC; glucotoxicity; cardiomyocyte; oxidative stress CARDIOVASCULAR COMPLICATIONS of diabetes have been recognized as the leading cause of morbidity and mortality in the diabetic population (22) . Hallmarks of cardiovascular injury in diabetes include cardiac diastolic with or without systolic dysfunction, myocardial hypertrophy, fibrosis. and microangiopathy (17) . Among the various signaling mechanisms identified to link the adverse effects of hyperglycemia with cardiovascular complications, the chronic activation of PKC, a serine/threonine protein kinase essential for a variety of cellular functions, has received increasing attention as a core effector that directs the toxicity of hyperglycemia to cell apoptosis, hypertrophy, fibrosis, and oxidative stress (5, 8, 29) . Existing data highlighted the conventional PKCs (cPKC) such as PKC isoforms ␣ and ␤ as the major mediator for cardiac glucotoxicity (12) . However, molecular mechanisms controlling myocardial cPKC activity in the context of hyperglycemia have not been completely understood.
Specific anchoring proteins serve as organizing centers for signal transduction by bringing kinases to their sites of action and linking effectors and substrates into close spatial proximity (38) . A kinase-anchoring proteins (AKAPs) have been shown to participate in the pathogenesis of cardiac arrhythmia (25) , heart failure (2), and hypertrophy (32) . The AKAP5 gene products (AKAP79 in human, AKAP150 in rodent, and AKAP75 in bovine) were first identified as a scaffolding protein that predominantly expressed in cerebral cortex and anchored the RII regulatory subunit of protein kinase A (PKA) to postsynaptic densities, wherein they participate in the regulation of excitatory synaptic transmission and neurotransmitter release (3) . Later studies have since demonstrated its capability to scaffold various kinases and phosphatases in excitable cells (neurons and myocytes), including calcium/ phospholipid-dependent PKC and Ca 2ϩ /calmodulin-dependent protein phosphatase calcineurin (16) . However, there are few studies addressing the anchoring of PKC by AKAP150 in cardiomyocytes, and of the role of AKAP150 in modulating myocardial PKC activity in diabetes is completely unknown.
Reactive oxygen species (ROS) play a pivotal role in the pathogenesis of diabetes-induced cardiac injury (27) . It has been suggested that high glucose levels stimulate ROS production through cPKC-dependent activation of NAD(P)H oxidase (Nox) (28) . cPKC has also been demonstrated to phosphorylate IB kinase and p65 NF-B, hence triggering NF-B translocation to the nucleus, where it activates transcription of genes involved in inflammatory and immune responses (20) . Therefore, identifying the organizing mechanics of cPKC-directed activation of NF-B and Nox may offer an alternative strategy permitting selective inhibition of cPKC-dependent cardiac glucotoxicity.
In this report, we demonstrate that cardiac AKAP150 is upregulated in response to hyperglycemic stimuli and functions to enhance the efficiency of glucotoxicity signaling through a cPKC/p47 phox /ROS pathway that induces cardiomyocyte apoptosis and oxidative stress.
MATERIALS AND METHODS
Animal models of diabetes. Male Sprague-Dawley (SD) rats weighing between 220 and 250 g were used to establish a diabetic animal model as described previously (35) . Diabetes was induced via intraperitoneal injection of streptozotocin (STZ, 35 mg/kg/day in 0.9% saline; Sigma, St. Louis, MO) for 3 days. Age-matched control rats were injected with an equal volume of saline. Animals were considered diabetic with blood glucose levels Ն16.7 mmol/l at 1 wk after STZ injection and were maintained for another 10 wk before randomization. Blood pressure was measured with a noninvasive blood pressure system (PanLab), and plasma insulin levels were measured with commercial ELISA kits (Cusabio Biotech) as described previously (35) . All experiments were approved by the Fourth Military Medical University Committee on Animal Care and were performed following the US National Institutes of Health Guidelines on the Use of Laboratory Animals.
Isolation and culture of neonatal rat cardiomyocytes. Neonatal rat cardiomyocytes (NRCMs) were isolated from 1-to 3-day-old SD rats (euthanized by cervical dislocation) as described previously (10) . Briefly, left ventricles of rats were isolated and cut into small pieces.
The tissue pieces were washed with Dulbecco's modified Eagle medium (DMEM) and enzymatically digested with 1 mg/ml type I collagenase (Invitrogen, Carlsbad, CA) in phosphate-buffered saline at 37°C with constant stirring. The supernatant from the initial digestion was discarded, fresh enzyme solution was added, and the digestion procedure was repeated six times. The resultant supernatants were collected and centrifuged at 1,000 g for 5 min. The collected cells were cultured in DMEM supplemented with 10% fetal calf serum and 1% penicillin-streptomycin in humid air with 5% CO 2 at 37°C. After 1.5 h of culture to allow fibroblast adherence, NRCMs were plated into a culture flask, and the culture medium was changed 48 h later to fresh DMEM medium with bromodeoxyuridine (BrdU, 0.1 mM) to inhibit fibroblast proliferation.
AKAP150 shRNA adenovirus construction. The rat AKAP150 mRNA sequence (Genbank no. NM_022059) was analyzed, and Fig. 1 . AKAP150 expression positively responds to high-glucose exposure along with PKC activation both in vivo and in vitro. A and B: AKAP150 mRNA and protein expression in vivo and in vitro as normalized to ␤-actin. C and D: membrane-to-cytosol expression ratio and total expression of PKC in vivo and in vitro. Na ϩ /K ϩ -ATPase and ␤-actin served as loading controls in membrane fractions or cytosol fractions, respectively. Normal, normal hearts; DM, hearts harvested from diabetic rats 13 wk after STZ injection; Control, normal cultured neonatal rat cardiomyocytes (NRCMS); HG, NRCMs cultured with 25 mM glucose for 48 h. Data points are means Ϯ SE; n ϭ 6 -8/group. **P Ͻ 0.01,*P Ͻ 0.05 vs. Normal; ##P Ͻ 0.01, #P Ͻ 0.05 vs. Control. 5=-GGCAAAGAGAAGTCGTCCT-3= was selected for shRNA target sequences. Negative control shRNA target sequence was 5=-TTCTC-CGAACGTGTCACGT-3=. shRNA was synthesized and cloned into psiRNA-PTP1B entry vector (constructed by Genechem, China). Then, adenovirus vectors that carry shRNA and pAdTrack plasmid, respectively, were transfected together into HEK-293 cells by Lipofectamine 2000 (Invitrogen). After 48 h, the adenovirus particles were collected from supernatant and purified by cesium chloride gradient ultracentrifugation. The viral titer was titrated to 10 11 TU (transfection unit)/ml.
Experimental protocol. Animals were randomly assigned to six groups: a Sham group, where normal rats received intramyocardial injection of 100 l of normal saline; an NC/RNAi (RNA interference) group, where normal rats received intramyocardial injection of negative control (NC) shRNA or AKAP150 shRNA; a DMϩSham group, where diabetic rats received intramyocardial injection of 100 l of normal saline; and a DMϩNC/RNAi group, where diabetic rats received intramyocardial injection of NC shRNA or AKAP150 shRNA. Knockdown of AKAP150 gene in rat hearts was performed as described previously, using a shRNA silencing technique (26) . Briefly, rats were anesthetized with 2% isoflurane, and an incision was made between the fourth and fifth left ribs to expose the heart. AKAP150 shRNA (10 l) or negative control shRNA recombinant (10 11 TU) was mixed with 90 l of sterile 0.9% saline. Each animal received intramyocardial injection of 100 l of adenovirus solution at 10 sites into the anterolateral wall. Animals were prepared for further study 2 wk after shRNA treatment. Rats were euthanized with an overdose of pentobarbital sodium (250 mg/kg ip).
Cultured NRCMs were also randomized into six groups: a Control group, that was cultured in normal medium, an NC/RNAi group, that was infected with NC shRNA or AKAP150 shRNA adenovirus and cultured in normal medium, an HG group, that was cultured in medium supplemented with 25 mM glucose for 48 h, and an HGϩNC/ RNAi group, that was infected with NC shRNA or AKAP150 shRNA adenovirus and cultured in medium supplemented with 25 mM glucose for 48 h. NRCMs cultured in medium containing 5.5 mM glucose and 19.5 mM mannitol were introduced as an osmotic control. For AKAP150 knockdown in vitro, NRCMs were infected with 8 g/ml polybrene (Sigma) and 50 MOI (multiplicities of infection) of AKAP150 shRNA or NC shRNA for 8 h and transferred to normal medium to terminate infection. The mRNA and protein levels of AKAP150 were analyzed by RT-PCR and Western blot 7 days after infection to determine the interference efficiency of AKAP150 shRNA.
Membrane fraction preparation from cardiac tissues and NRCMs. Extraction and purification of membrane protein from cardiac tissues or NRCMs were performed as described previously (18) . Briefly, cardiac tissues or NRCMs were lysed and homogenized. The crude homogenate was precleaned by centrifugation at 25,000 g for 30 min. The supernatant (cytosolic fraction) was collected, and the remaining pellet was resuspended in homogenization buffer without sucrose containing 0.1% Triton X-100. Supernatant containing the membrane fraction was collected following centrifugation at 25,000 g for 30 min.
Cardiac function assessment by echocardiography. Cardiac geometry and function were performed by ultrasound device (VisualSonics, Toronto, ON, Canada) with a 21-MHz linear transducer. Rats were reanesthetized with 2% isoflurane. Left ventricular end-diastolic diameter (LVEDD) and fraction shortening (FS) were recorded from M-mode tracings. The peak velocities of early-and late-filling waves were measured by pulsed-wave doppler spectra of mitral inflow from an apical four-chamber view. Left ventricular diastolic filling was assessed by the early/late mitral diastolic wave (E/A) ratios.
RT-PCR and western blot analysis. Total RNA was extracted using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. Total RNA was reverse transcribed into complementary DNAs (cDNAs), utilizing the M-MLV System (Promega). PCR amplifications were then performed using the following primers: AKAP150, 5=-TTG TGAGGGACACGGACTA-3= (forward) and 5=-GAGGAC-TGGCTGCTTCTG-3= (reverse); ␤-actin, 5=-TCAGGTCATCAC-TATCGGCAAT-3= (forward) and 5=-AAAGAAAGGGTGTA-AAACGCA-3= (reverse). Each RT-PCR product was analyzed by electrophoresis in agarose gel. PCR amplification signals were quantified by densitometric scanning using Quantity One (Bio-Rad). AKAP150 gene expression was normalized to ␤-actin gene expression.
Western blot was performed as previously described (39) . Primary antibodies included antibodies against AKAP150, cPKC(␣, ␤, ␥; 1:1,000, Millipore), NF-B subunit p65 (p65 NF-B), phospho-p65 NF-B, Nox subunit p47 phox , phospho-p47 phox , Na ϩ /K ϩ -ATPase, and ␤-actin (1:1,000, Sigma).
Apoptosis determination by TUNEL staining, caspase-3 assay, and flow cytometry. Cardiomyocyte apoptosis in ventricular tissues and in vitro NRCMs were detected by terminal deoxynucleotidyltransferasemediated dUTP nick-end labeling (TUNEL) using a TUNEL Kit (Roche, Germany) according to the manufacturer's protocol. Additional staining was performed with monoclonal anti-␣-sarcomeric actin (Sigma). The index of apoptosis was expressed as the proportion of TUNEL-positive cells to the total cells in percentage. Myocardial caspase-3 activity was performed using tissue homogenates and a caspase-3 colorimetric assay kit (Keygen, China) following the manufacturer's instructions. The NRCM apoptotic cells were also confirmed using annexin V-fluorescein isothiocyanate (Annexin V-FITC) and propidium iodide (PI) double staining followed by flow cytometry (19) .
ROS measurement and lipid peroxidation evaluation. Intracellular O 2
Ϫ was probed with dihydroethidium (DHE, 5 M) followed by confocal imaging. NRCMs were harvested and incubated with DHE for 1 h at 37°C in the dark. Fluorescence was visualized by fluorescence confocal microscopy (Nikon, Japan) and five campus visuals were randomly chosen. The quantification of fluorescent signals was analyzed by ImageJ software. For analysis of intracellular H 2O2 level, NRCMs were incubated with dichlorofluorescin diacetate (DCFH-DA, 5 M) at room temperature for 30 min in the dark and analyzed immediately by flow cytometry.
Lipid peroxidation was measured with malondialdehyde (MDA) assay kits (Beyotime, China) according to the manufacturer's instructions. Briefly, cell lysates were incubated with thiobarbituric acid (TBA) to generate the MDA-TBA adduct. The fluorescence intensity of MDA-TBA adduct was recorded by a fluorospectrophotometer (Tianjing, China), and the results were normalized to controls. Nox and PKC activity assay. The activity of Nox was measured by lucigenin-enhanced chemiluminescence using a commercial assay kit (Genmed, China) according to the manufacturer's instructions. Total cell lysates (100 g protein) were incubated with lucigenin at 37°C for 3 min. Lucigenin was deoxidized by Nox-derived superoxide anion, and the energetics of deoxidation represents the activity of Nox. Samples RLUs (relative light units) were continuously measured for 15 min by chemiluminescence using Appliskan luminometer (Thermo, USA). The recorded RLU was calculated to represent the Nox activity.
PKC activity was measured using Non-Radioactive Detection of Protein Kinase C (Promega) (34) . Briefly, total cell lysates were incubated with a positively-charged, fluorescent, and PKC-specific peptide for 30 min. The phosphorylated, negatively-charged peptide and the nonphosphorylated, positively-charged peptide were separated by electrophoresis in agarose gels. Resulting bands were visualized under UV light and quantified by densitometry. Data were normalized to controls.
Immunofluorescence and coimmunoprecipitation. The subcellular colocalization of AKAP150 and PKC was examined by immunofluorescence. After being fixed and permeabilized, ventricular tissue sections and in vitro NRCMs were incubated with antibodies against AKAP150 and cPKC (Sigma) at 1:100 dilution at 4°C overnight. Alexa fluor 633-nm goat anti-rabbit and Alexa fluor 488-nm donkey anti-mouse IgG served as secondary antibodies at a 1:500 dilution. Fluorescence was detected by confocal microscopy (Nikon). Parallel studies using antibodies against PKC␣, PKC␤, or PKC␥ were performed to investigate isoform-specific colocalization of PKC with AKAP150. The functional binding of AKAP150 and cPKC in NRCMs was further investigated by coimmunoprecipitation according to the manufacturer's protocol (Thermo). Briefly, resins were coated with 20 g of AKAP150 antibodies for coupling at room temperature for 2 h. Total NRCM lysates and resins were incubated with gentle agitation overnight at 4°C. The immune complexes were eluted from antibody-coupled resins. Western blot was carried out using cPKC antibodies to detect the cPKC content in the immune complexes.
Statistical analysis. All values are presented as means Ϯ SE. Data were analyzed by unpaired two-tailed t-test or one-way ANOVA followed by Bonferroni correction for post hoc t-test. A P value of Ͻ0.05 was considered statistically significant. All analyses were performed using GraphPad Prism 5.0 statistical software.
RESULTS

AKAP150 expression positively responds to high glucose exposure both in vivo and in vitro.
To determine whether high-glucose exposure affected cardiomyocyte AKAP150 expression, RT-PCR and Western blotting were performed to examine the changes of AKAP150 mRNA and protein expression in both cardiac tissues from diabetic animals and high-glucose cultured NRCMs. As shown in Fig. 1, A and B, compared with normal animals, both AKAP150 mRNA and protein levels increased significantly in diabetic myocardium. Similar increases were also observed in cultured NRCMs following 48 h of 25 mM glucose exposure. A time-dependent elevation was noted as high-glucose exposure prolonged from 24 h to 48 h.
Previous studies have suggested that diabetes increases myocardial expression and activation of cPKC (9) , and cPKCmediated activation of NF-B and Nox has been implicated in hyperglycemia-induced cardiovascular inflammation, oxidative stress, and apoptosis. Thus, we further examined the expression and activation of cPKC and its downstream molecules NF-B and Nox following high-glucose exposure. As expected, both total and membrane/cytosol expression of cPKC increased in diabetic hearts and high-glucose-treated NRCMs (Fig. 1, C and D) , indicating upregulated cardiac cPKC signaling after high-glucose exposure. In addition, the expression and phosphorylation levels of p65 NF-B and p47 phox , two known phosphorylation targets of cPKC and key regulatory subunits of NF-B and Nox respectively, also increased in both diabetic hearts and high-glucose-treated NRCMs (Fig. 2) . It is noteworthy that the minimal changes in mannitol-treated NRCMs excluded the role of osmotic alteration in activation of AKAP150/cPKC signaling (Fig. 3) .
AKAP150 knockdown alleviates diabetes-induced LVEDD and myocardial apoptosis. RNAi was used to test whether reduced expression of this anchoring protein perturbed cardiac functional phenotypes following hyperglycemic stimuli. RT-PCR and Western blot analysis demonstrated a nearly 60% decrease of myocardial AKAP150 expression 2 wk after intramyocardial injection of AKAP150 shRNA (Fig. 4, A and B) . General characteristics of rats in different groups were shown in Table 1 . Compared with Sham hearts, diabetic rats exhibited significantly compromised left ventricular diastolic dysfunction, as manifested by decreased LVEDD and E/A ratio (Fig. 4,  C and D) . However, AKAP150 knockdown in the diabetic hearts resulted in a robust increase in LVEDD and E/A ratio but no significant change in fractional shortening (Fig. 4E) , indicating a pivotal role of AKAP150 in diabetes-induced myocardial diastolic dysfunction. Moreover, cell apoptosis has been repeatedly documented to be one of the key mechanisms underlying diabetes-related functional injury. We next sought to determine whether AKAP150 plays a role in hyperglycemiainduced cardiomyocyte apoptosis. As expected, AKAP150 knockdown significantly reduced TUNEL-positively stained cells and caspase-3 activity in the diabetic hearts compared with the DMϩNC group (Fig. 4, F-H) .
AKAP150 knockdown inhibits high-glucose-induced apoptosis in NRCMs.
RT-PCR showed that AKAP150 transcripts reduced by ϳ70% 7 days after shRNA infection of NRCMs (Fig. 5A ). AKAP150 protein level demonstrated a nearly 60% decrease in the normally cultured cells (Fig. 5B ) and a 50% decrease in the high-glucose-treated cells (Fig. 5C) . Consistent with the data from in vivo studies, high-glucose culture markedly increased TUNEL-positive cells, which could be largely reversed by AKAP150 knockdown but not the NC shRNA infection (Fig. 5, D and E) . Similarly, annexin V/PI flow cytometry showed 21.6 Ϯ 3.2% of early-to mid-apoptotic cells after high-glucose exposure compared with 4.6 Ϯ 1.1% of apoptotic cells detected in the control group. When AKAP150 Data points are means Ϯ SE, n ϭ 10/group. Sham, normal rats received intramyocardial injection of 100 l normal saline; NC/RNAi, normal rats received intramyocardial injection of negative control (NC) shRNA or AKAP150 shRNA; DMϩSham, diabetic rats received intramyocardial injection of 100 l normal saline; DMϩNC/RNAi, diabetic rats received intramyocardial injection of negative control shRNA or AKAP150 shRNA. *P Ͻ 0.05 vs. Sham; #P Ͻ 0.05 vs. 1 wk after STZ injection.
was downregulated, the percentage of apoptotic cells was reduced to 12.2 Ϯ 1.6% (Fig. 5F ). These data suggest that downreguation of AKAP150 renders the cardiomyocytes more resistant to high-glucose-induced apoptosis.
AKAP150 knockdown reduces high-glucose-induced oxidative stress in NRCMs.
Oxidative stress is well recognized as a major contributor to high-glucose-induced cardiomyocyte apoptosis. Thus, we next investigated whether reduced cardiomyocyte susceptibility to glucose toxicity was associated with depressed ROS production due to AKAP150 knockdown. Confocal imaging and flow cytometry showed remarkable increases in DHE fluorescent signal (Fig. 6, A and B) and the percentage of DCFH positively stained cells (Fig. 6C ) in high-glucose medium, and AKAP150 knockdown significantly reversed high-glucoseinduced increases in ROS production. Moreover, AKAP150-targeted shRNA also suppressed the high-glucose-induced increase in Nox activity and lipid peroxidation as assessed by lucigenin-enhanced chemiluminescence and cellular malondialdehyde level, respectively (Fig. 6, D and E) .
AKAP150 is required for high-glucose-induced activation of cPKC. Hyperglycemia is linked to cellular DAG accumulation and subsequent activation of cPKCs, which contributes to a variety of cardiovascular pathologies such as apoptosis and oxidative stress. We therefore tested the hypothesis that AKAP predisposes the cardiomyocyte to glucotoxicity through its regulation of cPKC. The translocation of PKCs from cytoplasm to cytomembrane is considered a hallmark of PKC activation. We found that the high-glucose-induced increase in cPKC membrane translocation was markedly inhibited by AKAP150 knockdown, whereas total cPKC was not affected. The membrane/cytosol ratio of cPKC protein levels (Fig. 7, A and B) as well as PKC activity (Fig. 7C) showed a similar change in AKAP150-downregulated cells. These results indicated that high-glucose-mediated PKC activation is dependent on the functional expression of AKAP150 scaffolding protein.
AKAP150 knockdown inhibites high-glucose-induced activation of NF-B and Nox.
We next investigated whether reduced apoptosis and ROS production in AKAP150-downregulated NRCMs was associated with inhibition of NF-B and Nox signaling, two known phosphorylation targets of cPKC involved in inflammatory and oxidative responses. Increased cPKC activation in NRCMs following high-glucose exposure was accompanied by significant increases in both expression and phosphorylation of p65 NF-B (Fig. 8, A-C) , and, more importantly, AKAP150 knockdown inhibited highglucose-induced p65 NF-B phosphorylation, a critical event that determines nucleus translocation and subsequent NF-B activation (1) . Similarly, AKAP150 knockdown also suppressed high-glucose-induced increase in the phosphorylation of p47 phox (Fig. 8, D-F) , a vital Nox subunit whose phosphorylation is linked to Nox reassembly and activation (31) . These data suggested that AKAP150 suppression largely blocked activation of NF-B and Nox in cardiomyocytes exposed to high glucose.
AKAP150 colocalizes and functionally binds with cPKC. The above findings that AKAP150 contributes to cPKC activation and regulates its downstream signaling in high-glucosetreated NRCMs raised the question whether AKAP150 directly interacts with cPKC as a functional entity. We next performed immunocytochemical analysis to identify colocalizaiton of AKAP150 and cPKC in NRCM subcellular locations. Confocal imaging from multiple acquisitions indicated overlap of AKAP150 and cPKC fluorescence near the inner plasma membrane. More importantly, the colocalized fluorescence of AKAP150 and cPKC in the high-glucose group was markedly higher than in the control group, with significant increases in both total expression and membrane distribution of AKAP150 and cPKC. However, when AKAP150 was downregulated, both cPKC membrane translocation and levels of AKAP150 and cPKC colocalization were significantly reduced (Fig. 9A) . The colocalization of AKAP150 with cPKC was also identified in the diabetic myocardium (Fig. 10) . Further immunoprecipitation analyses were conducted to confirm the functional binding of AKAP150 with cPKC. Consistent with the results from confocal immunofluoresence, which showed minimal membrane expression of cPKC, tiny traces of cPKC were detected in the immune complex from normal cultured NRCM lysates.
However, significantly higher levels of AKAP150 coimmunoprecipitated with cPKC in high-glucose treated cells, and inhibition of AKAP150 reversed the high-glucose-induced increase in cPKC protein content in the immune complex (Fig.  9, B and C) . Our data revealed that AKAP150 and cPKC formed a molecular complex and high glucose increased levels of colocalization of AKAP150 with cPKC in cardiomyocytes.
PKC␣ and -␤ are preferentially mobilized by AKAP150 anchoring. Antibodies against different cPKC isoforms were used for immunocytochemical analysis to investigate whether all isoforms were involved or a specific one was preferentially mobilized by AKAP150 anchoring. Confocal imaging showed high levels of PKC␣ and -␤ coexpression with AKAP150 in NRCMs cultured with high glucose, in contrast to a lower level of PKC␥ colocalization with AKAP150 (Fig. 11A) . Furthermore, safingol (a PKC␣-specific inhibitor, 40 mol/l, Sigma) (30) and LY333531 (a PKC␤-specific inhibitor, 10 nmol/l, Merck) (36) both significantly reduced high-glucose-induced increases in apoptosis and ROS production in NRCMs (Fig. 11 , B and C). These data suggest that AKAP150 preferentially colocalizes with PKC␣ and -␤, which are the major isoforms responsible for cardiac glucotoxicity.
DISCUSSION
In the present study, we identified AKAP150 as a previously unrecognized protein that selectively directs glucotoxicity to transcriptional machinery that potentiated myocardial diastolic dysfunction, cardiomyocyte apoptotic response, and oxidative damage. We provided the first evidence for a pivotal role of the AKAP150 anchoring protein in diabetic hearts and described a signaling model where AKAP150 facilitated membrane translocation and activation of cPKC, preferentially isoforms ␣ and ␤, which in turn phosphorylated p65 NF-B and p47 phox and subsequently activated NF-B and Nox in the context of high glucose. We now implicate AKAP150 as a cofactor that amplifies cPKC signaling to NF-B and Nox to initiate a cardiac glucotoxicity phenotype.
AKAPs were originally identified as a family of proteins that share the ability to bind the regulatory subunit of PKA. The roles of AKAPs are to localize, specify, amplify, and accelerate intracellular signal transduction by linking upstream signal generators to downstream effectors or by recruiting multiple signaling enzymes within the signaling hub (11) . AKAP150, an important member of the AKAP family, has been investigated intensively during the past few decades. However, existing data largely focused on its regulation of the nervous system, such as peripheral inflammatory hyperalgesia (13) , neuron excitability (14) and neuroendocrine function (4), and its role in cardiovascular pathophysiology remained poorly understood. Earlier studies involving cardiac AKAP150 was based mainly on its consensus calcineurin-binding domain as a potent inhibitor of calcineurin activity to inhibit calcineurin-dependent hypertrophy (6). Nichols et al. (24) recently demonstrated that, in cardiac myocytes, AKAP150 mediates the association of ␤ 1/2 -adrenergic receptors, AC5/6, PKA, calcineurin, and L-type Ca 2ϩ channels, facilitating the selective PKA phosphorylation of proteins that regulate intracellular calcium in response to sympathetic stimulation. In contrast, in arterial myocytes, AKAP150-targeted PKC signaling, but not PKA, controls the L-type Ca 2ϩ channel function and Ca 2ϩ influx and, hence, regulates vascular tone and mediated angiotensin IIinduced hypertension (23) . However, it is completely unknown whether AKAP150 is involved in diabetic heart injury.
The present study observed a significant increase in the mRNA and protein expression of AKAP150 in both diabetic hearts and high-glucose-treated NRCMs, indicating that endogenous AKAP150 responds positively to high-glucose stimuli at both transcriptional and translational levels. More importantly, data from in vivo and in vitro models of AKAP150 knockdown showed that AKAP150 downregulation resulted in a significantly improved diastolic function and reduced myocardial apoptosis in diabetic hearts and a rescued phenotype in NRCMs exposed to high glucose with reduced apoptosis and oxidative stress. These data provided the first evidence for the involvement of AKAP150 in the development of cardiac toxicity of hyperglycemia. Unfortunately, it is still unclear how high glucose switches AKAP150 transcription on. Possible explanations may involve regulatory pathways via glucose metabolic intermediates or direct glucose-responsive machinery mediated by carbohydrate response element (ChRE) in the AKAP150 promoter (21, 33) . The molecular mechanisms underlying AKAP150 responsiveness upon hyperglycemic stimuli deserve further investigations.
Multiple biochemical pathways have been proposed to link the adverse effects of hyperglycemia with myocardial complications. Cellular mechanisms include increased activation of the polyol, nonenzymatic glycation, and advanced glycation end product pathways, enhanced reactive oxygen production and actions, and activation of the diacylglycerol (DAG)-PKC pathway. The central role of DAG synthesized from glycolytic intermediate dihydroxyacetone phosphate has been studied extensively in hyperglycemia-induced PKC activation. DAGtriggered PKC translocation represents a classic allosteric activation of PKC that allows substrate binding and phosphorylation followed by activation of downstream effectors (15) . Besides the well-studied DAG, however, AKAPs have also been recently shown to tether PKC isozymes to membranes (37) . In the present study, the elevated AKAP150 expression in response to high glucose was accompanied by increased cPKC membrane translocation and activation as well as phosphorylation of p65 NF-B and p47 phox , two major phosphorylation targets of cPKC involved in apoptotic and oxidative signaling. Furthermore, knockdown of AKAP150 abolished high-glucose-induced membrane translocation of cPKC and phosphorylation of p65 NF-B and p47 phox . These data demonstrated a critical role of AKAP150 in the activation of cPKC and scaffolding of cPKC signaling complexes following highglucose exposure, thus delineating a novel AKAP150-PKC pathway in cardiac response to hyperglycemia, and provided new insight into the regulational machinery of PKC activity under the control of glucose levels.
Previous molecular and cellular approaches have demonstrated the ability of AKAP150 to direct its cohort of anchored enzymes toward selected transmembrane proteins to facilitate their efficient regulation (7) . The subcellular colocalization and virtual binding of AKAP150 and cPKC in this study were further confirmed by immunofluorescent coexpression and coimmunoprecipitation analysis, indicating a spatial presence of cPKC/AKAP150 complex to support AKAP150-coupled func- tional activation of cPKC. In addition, we further identified PKC␣ and -␤ as the predominant isoforms to be involved in AKAP150 anchoring and mobilization. The use of isoformspecific inhibitors has added to previous knowledge that PKC␣ and -␤ are the major players mediating glucose-related cardiac injury (9) . Further work will be necessary to determine how and to what extent pharmacological or genetic manipulation could specifically target cPKC phosphorylation of a particular substrate such as NF-B and Nox to reverse the glucotoxicity phenotype.
In conclusion, data from this study demonstrate that AKAP150 mobilizes a cPKC signaling complex in the heart, which contributes to compromised diastolic function, cardiomyocyte apoptosis, and oxidative stress following hyperglycemia exposure. Specifically, AKAP150 functions as an anchoring protein to promote cPKC membrane translocation and activation of its downstream targets NF-B and Nox. In light of this report, it would be important to examine cardiac AKAP150-cPKC signaling in the diabetic population and explore whether AKAP150 could be used as a valid biomarker for cardiovascular complications of diabetes. Moreover, a more complete understanding of the structure-function relationships of the AKAP150-cPKC complexes may result in alternative therapeutic strategies by disruption of the unique protein-protein interactions and permit selective inhibition of cellular processes in the context of glucotoxicity, which may move clinical pharmacology beyond receptor ligands and enzyme inhibitors.
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